WebSep 18, 2024 · In the trastuzumab deruxtecan arm, 62.1% of patients had prior pertuzumab and 16.1% received another anti-HER2 tyrosine kinase inhibitor; these rates were 60.1% and 13.7%, respectively, in the T ... WebDec 11, 2024 · 612 n engl j med 382;7 nejm.orgFebruary 13, 2024 The new england journal of medicine were randomly assigned in a 1:1:1 ratio to re-ceive trastuzumab …
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WebApr 13, 2024 · Purpose: Over the past twenty years, anti-HER2 targeted therapies have proven to be a revolution in the management of human epidermal growth receptor 2 … WebJun 5, 2024 · QUICK TAKE Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer 02:11. Approximately 60% of human epidermal growth factor receptor 2 … dani dj valencia
Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2 ...
WebSep 18, 2024 · DESTINY-Breast03 randomized 524 patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab and taxane, to receive either trastuzumab deruxtecan 5.4 mg/kg every 3 weeks or T-DM1 3.6 mg/kg every 3 weeks. Patients with clinically stable, treated brain metastases were eligible for enrollment. WebSep 22, 2024 · Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Trastuzumab Deruxtecan in HER2-Low Breast Cancer N Engl J Med. 2024 Sep 22;387(12):1144. doi: … WebJan 8, 2024 · Two new treatment options are emerging for women with metastatic breast cancer, following positive results from clinical trials. The trials tested the drugs tucatinib … dani daortiz book